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Role of calcification inhibitors in the pathogenesis of vascular
calcification in chronic kidney disease (CKD).
Background. The majority of patients with chronic kidney
disease (CKD) have excessive vascular calcification; however,
most studies demonstrate that a subset of CKD patients do not
have, nor develop, vascular calcification despite similar expo-
sure to the uremic environment. This suggests protective mech-
anisms, or naturally occurring inhibitors, of calcification may be
important.
Methods. In order to determine the role of three inhibitors,
fetuin-A, matrix gla protein (MGP), and osteoprotegerin
(OPG) in the vascular calcification observed in patients with
CKD-5, we (1) measured serum levels of these inhibitors and
compared the levels to calcification assessed by computed to-
mography (CT); (2) examined arteries from CKD-5 patients by
immunostaining for these inhibitors; and (3) examined the ex-
pression and effect of these inhibitors in cultured bovine vascu-
lar smooth muscle cells (BVSMCs) incubated in serum pooled
from uremic patients compared to healthy controls.
Results. There was a negative correlation of coronary artery
calcification scores with serum fetuin-A levels (r = −0.30, P =
0.034) and a positive association with OPG levels (r = 0.29, P =
0.045). There was increasing immunostaining for both fetuin-
A and MGP in arteries with increasing calcification graded
semiquantitatively (P < 0.003). In vitro, fetuin-A added to
mineralizing BVSMCs inhibited mineralization (P < 0.001).
Compared to normal serum, BVSMCs incubated with uremic
serum had a progressive increase in MGP expression with min-
eralization (P < 0.001) and increased expression of OPG in
BVSMCs (P < 0.04).
Conclusion. These data demonstrate that fetuin-A, OPG, and
MGP play an important role in the pathogenesis of uremic vas-
cular calcification.
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Cardiovascular disease and stroke is the leading cause
of death in patients with end-stage renal disease (ESRD)
that require dialysis [chronic kidney disease, stage 5
(CKD-5)], at a risk that is 10- to 20 -fold the age-
and gender-matched general population[1]. However,
traditional Framingham risk factors can not completely
account for the excessive prevalence [2], suggesting dial-
ysis specific risk factors may contribute. Recent data have
linked hyperphosphatemia and elevations in the calcium
× phosphorus product in CKD-5 patients with increased
mortality [3]. In addition, studies have linked these dis-
orders of mineral metabolism with vascular calcification
in vitro, in vivo animal models, and in human studies (re-
viewed in [4]).
A study evaluating coronary calcification by electron-
beam computed tomography scan (EBCT) in patients
with ESRD has demonstrated two- to fivefold more coro-
nary artery calcification than age- and gender-matched
individuals with angiographically proven coronary artery
disease [5]. Histologic analyses confirm increased calcifi-
cation of arterial lesions from dialysis patients compared
to the general population with known coronary artery
disease [6]. Others have demonstrated that this process
is rampant, even in children and young adults [7]. Fur-
thermore, the presence of vascular calcification may have
prognostic implications for dialysis patients. Indeed, the
greater the degree of peripheral vascular calcification by
ultrasound [8] and plain radiographs [9], and coronary
artery disease by helical CT [10], the greater risk of mor-
tality. Despite this high prevalence of vascular calcifica-
tion, in most series 0% to 50% (mean 17%) of CKD
subjects studied do not have detectable vascular calcifi-
cation, despite similar risk factors (reviewed in [11]). Fur-
thermore, patients who do not have vascular calcification
rarely develop calcification on follow-up [10]. While this
is in part due to younger age, these data also imply a po-
tential role of naturally occurring inhibitors of vascular
calcification. Even in non-CKD patients, serum is super-
saturated with respect to calcium phosphate, and thus
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inhibitors must exist to prevent widespread extraskeletal
ossification [12].
Recent animal “knockout” models have shown that
key gene products may be protective of vascular
calcification including matrix gla protein (MGP), osteo-
protegerin (OPG), and fetuin-A (a2-Heremans-Schmid
glycoprotein) (Ahsg). Animals deficient in OPG [13] and
MGP [14] develop spontaneous medial calcification of
arteries. Animals deficient in fetuin-A, when bred on
a DBA/2 background or fed a high calcium diet also
develop extraskeletal calcification, including soft tissue
and perivertebral arterial calcification [15]. We therefore
hypothesized that naturally occurring inhibitors may be
deficient or aberrantly regulated in CKD patients with
vascular calcification. Specifically, we hypothesized that
fetuin-A, OPG, and MGP are important inhibitors of
vascular calcification in CKD-5 patients. To test this hy-
pothesis, we performed a series of experiments: (1) we
measured these inhibitors in vivo in the serum of CKD-5
subjects and determined the association of serum levels
with the magnitude of coronary artery and aorta calcifi-
cation quantified by spiral CT; (2) we assessed the pres-
ence of these inhibitors by immunostaining in arteries
obtained from CKD-5 patients with and without calci-
fication; (3) in vitro experiments were done to deter-
mine expression of these inhibitors in bovine vascular
smooth muscle cells (BVSMCs) incubated with pooled
serum from dialysis patients compared to pooled normal
healthy control human serum; and (4) we determined the
ability of fetuin-A and OPG to inhibit mineralization in
BVSMCs. The results demonstrate a role for all three
inhibitors in the vascular calcification observed in CKD.
METHODS
Association of vascular calcification and serum levels
of inhibitors
We measured fetuin-A, OPG, and MGP levels in serum
from patients with ESRD who were undergoing assess-
ment of coronary artery and aorta calcification by spi-
ral CT to determine the relationship of calcification and
serum inhibitor levels. The patient characteristics and cal-
cification scores have been previously published [10, 16].
Briefly, the patients consisted of two cohorts, a group of
30 hemodialysis patients and a group of 38 patients under-
going a renal transplant. All but two of this latter group
were undergoing dialysis. CT scans were performed with
quad-slice technique on the model MX 8000 scanner us-
ing a retrospective gating protocol with a threshold of
130 Hounsfield units (Philips Medical Systems, Cleve-
land, OH, USA) as previously described in detail [17].
A single reader scored each coronary artery, the summa-
tion of which was the total coronary artery calcification
score.
As previously published, in both cohorts, only advanc-
ing age and duration of dialysis were associated with the
coronary artery calcification score, and only advanced
age was associated with aorta calcification score [17].
For the present study, these two groups are combined
for a cross-sectional analysis of the association of the
coronary artery calcification scores and aorta scores with
serum levels of inhibitors. Because this is a secondary
analysis using stored serum, not all patients had enough
serum for all analyses, thus the final number (N) for
each serum test differs. The fetuin-A was measured by
nephelometry using antihuman fetuin-A antibody from
Chiron Behring, Marburg, Germany [18], MGP was mea-
sured by enzyme-linked immunosorbent assay (ELISA)
(Biomedica, Vienna, Austria), and OPG was measured
by ELISA (Alpco Diagnostics, Windham, NH, USA). In
the cohort who received a renal transplant, additional
serum levels were measured 15 to 20 months later in some
patients to determine the net change in serum levels of
inhibitors with a functional allograft.
Determination of expression of inhibitors in arteries with
and without calcification
As previously described, we have performed immunos-
taining using standard methodology on paraffin sec-
tions of inferior epigastric arteries obtained from pa-
tients undergoing renal transplantation, demonstrating
the presence of medial calcification in association with
the expression of “bone” matrix proteins and transcrip-
tion factors [16]. During the surgery, the proximal infe-
rior epigastric artery was ligated and a 2 to 3 cm piece of
vessel was removed and placed into 4% paraformalde-
hyde, followed by paraffin embedding and sectioning [16].
MacNeal’s stain was also done, which uses a combina-
tion of tetrachrome solution for blue nuclear staining, to-
gether with silver stain to highlight calcification. For the
present study, unstained slides from these tissue sections
were deparaffinized in xylene and rehydrated in descend-
ing alcohol, followed by 3% hydrogen peroxide and wash-
ing in Tris saline. Sections were blocked by 3% bovine
serum albumin (BSA) (Sigma Chemical Co., St. Louis,
MO, USA) for 15 minutes, and then incubated for 1 hour
in the primary antibody, human fetuin-A (antiserum di-
luted 1:1000 in blocking buffer) or human matrix gla
protein (1:200 from Dr. Reider Wallin, Wake Forest Uni-
versity, NC, USA). The sections were then incubated with
ABC staining system (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) followed by color development with di-
aminobenzidine (DAB), and counterstained with Harris
Hematoxylin (Sigma Chemical Co.). Staining without the
primary antibody served as a negative control. Unfortu-
nately, despite trying several commercially available and
other antibodies to OPG, none demonstrated consistent
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results with several controls and thus we were only able
to do immunostaining for fetuin-A and MGP.
Determination of expression of inhibitors in BVSMCs
incubated in the presence of pooled normal human or
pooled uremic human serum
We used cultures of BVSMCs, isolated as primary cul-
tures by the explant method as previously described [19].
The BVSMCs were incubated in Dulbecco’s modified
Eagle’s medium (DMEM) media (Sigma Chemical Co.),
with 10% serum for 24 to 72 hours, and then protein iso-
lated or mRNA isolated for assessment of fetuin-A or
OPG by Western blot, or MGP by reverse transcription-
polymerase chain reaction (RT-PCR). As previously de-
scribed [19, 20], the serum was either fetal bovine serum
(FBS) (Sigma Chemical Co.), pooled uremic serum from
patients undergoing hemodialysis without residual re-
nal function (uremic serum), or pooled serum from age
matched healthy controls (normal serum). In addition
we used a mineralization model where BVSMC were in-
cubated in 10 mmol/L b-glycerophosphate, 10 U/mL in-
sulin, and ascorbic acid in the presence of 15% serum.
In this model, the calcification over time was quantified
by extraction with HCl at various time points, as previ-
ously described [19]. In some experiments, conditioned
media were collected preincubation and postincubation
to determine secretion of OPG into culture media by
ELISA (Alpco Diagnostics) by net change (post minus
pre). In the OPG experiments, the osteoblast cell lines
Saos (ATCC, Manassas, VA, USA) were used as control
cells. In additional experiments designed to determine the
effect of inhibitors in mineralizing cultures of BVSMC,
we added fetuin-A (Sigma Chemical Co.) at doses of 100,
500, and 1000 lg/mL, or 200 ng/mL of OPG (R&D Lab-
oratories, Minneapolis, MN, USA) and assessed calcium
deposition at 7 and 14 days.
For the Western blot analyses, BVSMCs were grown
in a 6-well culture plate and incubated with the vari-
ous reagents for indicated times. Cells were then washed
with cold phosphate-buffered saline (PBS) and incu-
bated with ice-cold lysis buffer containing 5 mmol/L
Hepes (pH 7.9), 150 mmol/L NaCl, 26% glycerol
(vol/vol), 1.5 mmol/L MgCl2, 0.2 mmol/L ethylene-
diaminetetraacetic acid (EDTA), 0.5 mmol/L dithio-
threitol (DTT), and 0.5 mmol/L phenylmethylsulfonyl
fluoride (PMSF). Whole cell lysates (20 lg) were mixed
with equal volume of 4× Laemmli sample buffer.
The mixture and prestained molecular weight mark-
ers were boiled for 5 minutes and separated by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE). Proteins were electrophoretically trans-
ferred to a polyvinylidene diflouride (PVDF) membrane
(Millipore Corp., Bedford, MA, USA). The membrane
was blocked in Tris-buffered saline containing 5% non-
fat dry milk and 0.05% Tween-20 (TBST) for 1 hour,
then incubated overnight at 4◦C with rabbit antibodies
against bovine fetuin-A (IgG fraction, 3 lg/mL) or OPG
and RANK-L (1:100) (both from R&D Laboratories).
The membrane was washed with TBST buffer, then in-
cubated with goat antirabbit IgG peroxidase conjugate
(1:5000 dilution). Immunodetection was done with the
enhanced chemiluminescence (ECL) kit (NEN Life Sci-
ence Products, Boston, MA, USA). The band intensity
was analyzed by scanning densitometry (Molecular Anal-
ysis; Bio-Rad, Hercules, CA, USA).
The RT-PCR was performed using Titan one tube RT-
PCR kit (Roche Diagnostics, Indianapolis, IN, USA).
Briefly, total RNA was RT at 50◦C for 30 min-
utes followed by PCR reaction with Titan enzyme
mix (AMV reverse transcriptase and Taq DNA poly-
merase) in a 50 lL mixture containing 0.2 mmol/L
deoxynucleoside triphosphate (dNTP), 5 U RNAse
inhibitor, 5 mmol/L DTT, 20 pmol of sense and
antisense primers. The sense primer for MGP was
5′-TACCAGACCGAGACCAACAGAG-3′ and the an-
tisense primer was 5′-CACCACCGGGTCACGTCGC-
3′. The reaction went for 35 cycles consisting of 30 seconds
at 94◦C, 30 seconds at 55◦C, and 1 minute at 68◦C, fol-
lowed by a final extension step at 68◦C for 10 minutes be-
fore cooling at 4◦C. The RT-PCR products were resolved
on a 1.5% agarose gel and visualized by ethidium bro-
mide staining. The housekeeping gene b-actin was used
for internal control. The band density was analyzed by
scanning densitometry (Molecular Analysis; Bio-Rad).
Statistical analyses
The relationship of demographic, laboratory, and calci-
fication scores with serum levels of inhibitors was deter-
mined by Pearson correlation coefficients or Spearman
rank-sum analysis. Differences in levels of inhibitors in
patients with varying degrees of calcification were an-
alyzed by Mann-Whitney U test or analysis of variance
(ANOVA) with Tukey post hoc testing. Serum levels pre-
and posttransplant were analyzed by Mann-Whitney U
test. Immunostaining of arteries, or mineralization be-
tween groups of BVSMCs, were analyzed by ANOVA
with Tukey post hoc testing. All studies were approved
by the local Institutional Review Board.
RESULTS
In vivo studies
The serum level of fetuin-A was negatively correlated
with the coronary artery calcification score (r = −0.30,
P = 0.034) (N = 51), although the fetuin-A levels in
subjects with no calcification (0.51 ± 0.04) (N = 14) did
not differ from those with mild calcification (score 1 to
200) (0.47 ± 0.02) (N = 15) or with severe calcification
(score > 200) (0.44 ± 0.2) (N = 20) although a trend was
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present. There was no correlation with serum fetuin-A
levels and aorta calcification score, age, time on dialysis,
or serum levels of calcium, albumin, phosphorus, parathy-
roid hormone (PTH), and MGP. However the fetuin-A
levels were lower in males (0.45 ± 0.11) (N = 40) than
females (0.53 ± 0.16) (N = 19) (P = 0.019). The serum
levels of OPG were positively correlated with the magni-
tude of coronary artery calcification (r = 0.29, P = 0.045)
(N = 48). The serum levels of OPG were different with
different levels of calcification (no calcification 6.23 ±
0.68) (N = 18); coronary artery calcification scores of 1
to 200, 9.63 ± 0.96 (N = 19); and coronary artery calcifi-
cation >200, 11.16 ± 0.02 (N = 29) (P < 0.002). Further-
more, the serum OPG levels were greater in subjects with
coronary artery calcification (10.56 ± 0.69, range 2.86 to
29.48) (N = 48) than with no coronary artery calcification
(6.23 ± 0.68, range 1.47 to 12.06) (N = 18) (P = 0.001).
Similarly, the serum OPG levels were greater in subjects
with aorta calcification (10.88 ± 0.76, range 4.14–29.48)
(N = 35) compared to no aorta calcification (7.67 ± 0.81,
range 1.47–22.21) (N = 31) (P = 0.005). Serum OPG lev-
els correlated with duration of dialysis in months (r =
0.32, P = 0.008) (N = 68), and increasing age (r = 0.46, P
< 0.001) (N = 68), but did not correlate with serum levels
of PTH, calcium, phosphorus, or calcium × phosphorus
product. In contrast to fetuin-A and OPG levels, there
was no correlation of serum MGP levels (N = 54) and cal-
cification of the coronary arteries or aorta, no difference
in MGP in those with and without calcification, nor any
relationship with demographic or laboratory variables.
Further analyses were done to determine if a ratio of one
inhibitor to another, or a ratio of the calcium × phospho-
rus product to an inhibitor altered results. These analy-
ses demonstrated no change to the relationships stated
above.
To determine if the serum levels of these inhibitors
changed with a functioning renal allograft, we measured
serum levels in a subset of patients 15 to 20 months post-
transplant. Serum fetuin-A levels (N = 11) (P = 0.049)
and MGP levels (N = 11) (P = 0.042) increased after re-
nal transplant, whereas serum OPG levels declined (N =
19) (P < 0.001) after renal transplant in patients with a
well functioning allograft (Fig. 1).
Ex vivo studies
We analyzed the inferior epigastric artery obtained at
the time of renal transplant. Thirty-three arteries were of
sufficient quantity and quality to analyze for the presence
of mineralization by silver stain (MacNeal’s stain), and
for the relationship of the mineralization to immunos-
taining for fetuin-A and MGP, graded semiquantitatively
(0 to 4+). The results of the scoring are presented in
Figure 2, and demonstrate that as mineralization pro-
gresses histologically, there is increased immunostaining
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Fig. 1. Change in serum levels after renal transplantation. Patients had
serum level for fetuin-A (top panel), matrix gla protein (MGP) (middle
panel), and osteoprotegerin (OPG) (lower panel) at the time of renal
transplant, and approximately 15 months later with a well-functioning
allograft. The results show that serum levels for fetuin-A (P = 0.049)
(N = 11) and MGP (P = 0.042) (N = 11) increased posttransplant,
whereas OPG levels decrease (P < 0.001) (N = 19).
of both fetuin-A (P = 0.003) and MGP (P < 0.001). Rep-
resentative staining are shown in Figure 3 and although
there was a similar pattern of staining for fetuin-A and
MGP, there was not complete overlap and double staining
was not able to be performed.
In vitro studies
We have previously demonstrated that pooled hu-
man serum collected from dialysis patients can induce
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Fig. 2. Immunostaining for fetuin-A and matrix gla protein (MGP) in
inferior epigastric arteries. Arteries obtained at the time of renal trans-
plant were fixed and embedded in paraffin. The sections were stained by
MacNeal’s stain (black, calcification), and by immunostaining with anti-
fetuin-A () and MGP () and graded semiquantitatively (0 to 4+). The
result show a progressive increase in immunostaining with progressive
calcification (P = 0.003 for fetuin-A and P < 0.001 for MGP).
Fig. 3. Immunostaining for fetuin-A and matrix gla protein (MGP) in inferior epigastric artery. Arteries obtained at the time of renal transplant
were fixed and embedded in paraffin. The sections were stained by MacNeal’s stain (left column; black = calcification), and by immunostaining with
anti-fetuin-A (middle column) and MGP antibodies (right column). This panel demonstrated representative sections from a noncalcified artery
(upper row), 2+ calcified artery (middle row) and 4+ calcified artery (lower row). There was positive immunostaining for both fetuin-A and MGP
in areas of calcification (arrows in E, F, H, I).
mineralization in BVSMCs earlier and to a greater extent
than pooled normal human serum [19, 20]. Therefore,
we tested whether pooled uremic human serum also had
a differential effect compared to pooled normal human
serum in the local expression of calcification inhibitors.
Fetuin-A. As detailed above, the human arteries
demonstrated positive immunostaining for the presence
of fetuin-A when calcification was present. However, in
the adult, fetuin-A is only synthesized by the liver, and
is primarily deposited in bone [12]. To confirm this, we
examined BVSMCs incubated in the presence of albu-
min (no fetuin-A), FBS (large amounts bovine fetuin-A),
and human normal and uremic serum (contains human
fetuin-A), and examined cell lysate for fetuin-A content
by Western blot. The results demonstrated the presence
of fetuin-A in BVSMCs cultured with FBS and human
serum, but not albumin (data not shown) suggesting that
the cells take up fetuin-A rather than synthesize it.
To determine if fetuin-A could specifically inhibit min-
eralization, we incubated BVSMCs in the presence of cal-
cification media (b-glycerophosphate, insulin, and ascor-
bic acid) with 15% pooled human normal or uremic
serum. We then added increasing amounts of fetuin-A to
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Fig. 4. Fetuin-A inhibits mineralization of bovine vascular smooth
muscle cells (BVSMCs). BVSMCs were incubated in mineralizing con-
ditions (b-glycerophosphate, insulin, and ascorbic acid) in the presence
of normal control serum () or uremic serum () and fetuin-A added at
0, 100, 500, and 1000 lg/mL. Mineralization was assessed at 14 days with
HCl extraction. The results demonstrate that fetuin-A inhibits miner-
alization in both control and uremic treated BVSMCs. ∗P < 0.001 com-
pared to normal serum-treated BVSMCs without fetuin-A; +P < 0.01
compared to same serum-treated BVSMCs without fetuin-A.
the mineralizing cultures and determined net calcium de-
position by HCl extraction. The results show that 500 and
1000 lg/mL of added fetuin-A inhibited uremic serum
mineralization down to baseline levels of mineralization
observed in cells incubated with normal human serum
without additional fetuin-A. In addition, similar findings
were observed in BVSMCs incubated in the presence of
normal serum when 1000 lg/mL fetuin-A was added to
normal serum, indicating the inhibitory effects of fetuin-
A were observed in both normal and uremic serum, sug-
gesting that the fetuin-A inhibitory effects is not specific
(Fig. 4) (P < 0.01). Of importance, the levels of fetuin-A
in the pooled normal and uremic serum were not differ-
ent (0.6 and 0.5 g/L) and this difference would be fur-
ther minimized when the sera is diluted to 15% for the
experiments.
OPG. To determine if the effect of OPG is via the
vasculature, bone or both, we incubated BVSMCs and
Saos osteoblasts in the presence of pooled human nor-
mal or uremic serum and determined the expression of
OPG and RANK-L in cell lysate by Western blot. The re-
sults demonstrate that BVSMCs incubated with uremic
serum had increased expression of OPG (P = 0.008) and
RANK-L (P = 0.03) by Western Blot (Fig. 5, left panel)
compared to BVSMCs incubated with normal serum. In
contrast, uremic serum only increased RANK-L (P =
0.01), but not OPG in osteoblasts (Fig. 5, right panel). In
addition, BVSMCs incubated with uremic serum had a
net increase in secretion of OPG into the media (0.79 ±
0.12 pmol/L) (difference between media postincubation
and media preincubation) versus no detectable OPG se-
cretion in BVSMCs incubated in normal serum. When
BVSMCs were induced to mineralize in the presence of
uremic or normal serum with b-glycerophosphate, the
addition of 200 ng/mL of OPG [21] did not affect min-
eralization in either normal or uremic serum at day 7
or day 14 [day 7 normal, 100%; normal + OPG, 106 ±
6.8%; normal uremic, 124 ± 19.1%; uremic + OPG 132
± 12.4%; day 14 normal, 133 ± 6.7% normal day 7; nor-
mal + OPG, 139 ± 11.2%; uremic, 164 ± 19.1%; uremic
+ OPG, 166 ± 12.4% (N = 8 or 9 per group from three
separate experiments)].
MGP. To determine the role of MGP in uremic serum
induced vascular calcification, we examined BVSMCs in-
cubated in normal or uremic serum for 24, 48, or 72 hours
for the expression of MGP by RT-PCR. However, only
very faint expression was seen despite appropriate pos-
itive controls (data not shown). We then examined the
expression of MGP by RT-PCR during BVSMC incu-
bated in calcification media (b-glycerophosphate, insulin,
and ascorbic acid) and found that MGP expression pro-
gressively increased with time and mineralization (P <
0.001), and was greater in the BVSMCs incubated with
uremic serum compared to control human serum at 10
and 14 days (Fig. 6) (P < 0.001). Even if the expres-
sion of MGP was divided by the magnitude of calcifi-
cation at each time point (as calcification was greater in
uremic cultures), the expression was still greater in the
BVSMCs treated with uremic serum, indicating that at
a given level of calcification, MGP expression was still
greater in BVSMCs incubated with pooled uremic serum
compared to pooled normal serum. Unfortunately, MGP
is insoluble [22], and thus in vitro experiments could not
be done.
DISCUSSION
Vascular calcification in patients with CKD-5 is asso-
ciated with increased cardiovascular morbidity and mor-
tality [9, 10, 23]. However, studies evaluating the preva-
lence of vascular calcification indicate that from 0% to
50% (mean 17%) of patients on dialysis do not develop
vascular calcification (reviewed in [11]). Animal “knock-
out” studies provide further support that calcification is
normally actively inhibited in extraskeletal tissues, and
that a lack of activity or absence of these inhibitors must
be a factor when pathologic calcification occurs in ex-
traskeletal locations [12]. Given that most, but not all
CKD-5 patients, have vascular calcification there is likely
an important role for naturally occurring inhibitors in
the pathogenesis of vascular calcification in dialysis pa-
tients [24]. Each of the three inhibitors tested in this study,
fetuin-A, OPG, and MGP, appear to be involved in vas-
cular calcification, but differ in the magnitude and mech-
anism by which these proteins regulate calcification in
uremia.
In the present study, we demonstrated a weak asso-
ciation with lower fetuin-A serum levels in CKD-5 pa-
tients with greater levels of coronary artery calcification,
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Fig. 5. Osteoprotegerin (OPG) and RANK-
L expression in bovine vascular smooth mus-
cle cells (BVSMCs) and Saos osteoblasts.
BVSMCs (left panel) and osteoblasts (right
panel) were incubated in normal control hu-
man serum () or pooled uremic serum ()
and OPG and RANK-L expression assessed
in cell lysate by Western blot. In BVSMCs (left
panel), uremic serum increased the OPG (P
= 0.008) and RANK-L (P = 0.03) expression
in BVSMCs compared to normal serum. In
contrast, in osteoblasts (right panel) uremic
serum only increased RANK-L (P = 0.01),
but not OPG compared to normal serum.
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Fig. 6. Matrix gla protein (MGP) expression in mineralizing bovine
vascular smooth muscle cells (BVSMCs). BVSMCs were incubated in
mineralizing conditions (b-glycerophosphate and insulin) in the pres-
ence of healthy normal serum () or uremic serum () and MGP expres-
sion assessed at 7, 10, and 14 days by reverse transcription-polymerase
chain reaction (RT-PCR). The results demonstrate that MGP expres-
sion is increased in uremic serum treated BVSMCs during mineral-
ization (P < 0.001) and that at 10 and 14 days, uremic serum further
increases MGP compared to normal serum-treated cells. ∗P < 0.001.
although levels could not discriminate between those
with and without calcification. However, our observa-
tions are consistent with previous studies demonstrating
that low levels of fetuin-A are associated with increased
cardiovascular mortality in dialysis patients [18]. Low lev-
els of fetuin-A are also observed in dialysis patients with
calcific uremic arteriolopathy [15]. Furthermore, adding
fetuin-A back to serum of patients with calcific uremic
artriolopathy can reduce mineral precipitation in vitro.
Fetuin-A has diverse biologic activity, is constitutively
secreted by liver parenchyma cells, is an abundant circu-
lating protein in serum, and is primarily located in bone
(reviewed in [12]). Fetuin-A avidly binds calcium phos-
phate [25], and thus acts as a buffer of serum calcium-
phosphate to avoid extraskeletal calcification in states of
serum supersaturation. Indeed, the fetuin-A knockout
mice develop extraskeletal calcification, but only in situ-
ations of excess calcium by either feeding the animals cal-
cium and vitamin D, or breeding them on a strain of mice
predisposed to extraskeletal calcification [15]. This role of
fetuin-A as a serum “buffer” for calcium phosphate is also
consistent with our in vitro findings that fetuin-A dose-
dependently inhibited mineralization in BVSMCs, simi-
lar to previous data in osteoblasts [26]. Thus, our findings
of low serum levels of fetuin-A associated with vascular
calcification in dialysis patients may be due to decreased
(or overwhelmed) buffering capacity of serum in the pres-
ence of low serum fetuin-A levels, leading to extraskeletal
calcification.
We also demonstrated positive fetuin-A immunos-
taining of arteries of CKD-5 patients in areas of cal-
cification. However, we were unable to determine why
fetuin-A was localized to areas of calcification, although
there are several possible explanations. First, the fetuin-
A may bind excess calcium phosphate in the serum,
then precipitate to allow efficient removal by vascu-
lar smooth muscle cells of excess calcium phosphate
from the circulation. This is supported by data demon-
strating that fetuin-A facilitates the uptake of cationic
macrophage deactivating molecules in macrophages [27].
Similarly, a second alternative is that if the normal re-
moval system (presumably reticuloendothelial system)
is overwhelmed, this serum fetuin-mineral complex de-
posits into arteries leading to local cell injury and vascu-
lar abnormalities. Our findings that fetuin-A appeared to
be taken up, as opposed to synthesized, by the vascular
smooth muscle cells is consistent with either of these pos-
sibilities. A third possibility is that the fetuin-A-calcium-
phosphorus complex may also deposit in the vasculature
in states of abnormal bone remodeling. Price et al [28–31]
in a series of experiments has demonstrated that fetuin-A
complexed to calcium and phosphorus is released from
bone in a rat model of high turnover bone and vascular
calcification induced by high dose vitamin D. Further-
more, this vascular calcification could be inhibited in the
presence of bisphosphonates, and the serum levels of this
fetuin-A complex correlated with arterial calcification in
the rat. A last, less likely, possibility is that the serum
fetuin-A binds to calcium that is already deposited in the
arteries, acting as a “homing pigeon” to go to the deposits,
presumably as an attempt to stop extension of the deposit,
or enable phagocytosis of the deposit. Clearly, more work
is needed to fully understand the role of fetuin-A in the
regulation of vascular calcification.
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The interpretation of our OPG results is also complex.
OPG knockout mice develop arterial calcification, imply-
ing that OPG is an important inhibitor of vascular calcifi-
cation. However, in the present study, we demonstrated
that increased OPG serum levels were associated with in-
creased coronary artery and aorta calcification. This ap-
parent paradoxic association has also been observed in
the general population [32], and in hemodialysis patients
[33, 34]. There are several potential explanations for these
findings. One potential explanation is that the serum as-
says detect nonfunctional OPG fragments that are nor-
mally cleared in CKD. Supporting this is our finding
that serum levels decreased posttransplant, whereas both
fetuin-A and MGP levels increased. In addition, serum
OPG was positively correlated with decreasing creatinine
clearance and increased duration of dialysis, and vascular
calcification is more common with increased duration of
dialysis. Against this possibility is that multivariate anal-
ysis in the study by Nitta et al [33, 34] demonstrated OPG
levels were independent predictors of vascular calcifica-
tion, and the study Kazama et al [35] demonstrating that
serum from CKD patients was able to appropriately bind
RANK-L in vitro, suggesting intact biologic activity. A
second possibility is that the elevated serum OPG is re-
leased by BVSMCs that are calcifying, and therefore be-
having like osteoblasts. Our in vitro data support this, in
that uremic serum increased OPG and RANK-L produc-
tion by vascular smooth muscle cells. The role of OPG
in bone is to serve as a decoy receptor, binding to the
RANK-L receptor on osteoblasts, thereby preventing os-
teoclast binding and activation. Thus, it is possible that el-
evated OPG levels reflect an ongoing attempt of arteries
to remodel, supported by the observation of an occasional
osteoclast like cell in arterial calcification [36]. The lack of
effect of exogenously added OPG in vitro in our studies
may be due to the absence of osteoclast like cells in this
culture system. A third explanation for elevations in OPG
associated with arterial calcification is that the circulating
OPG is released from bone, and reflects the state of bone
turnover, which in turn determines the degree of vascu-
lar calcification. Data supporting this view include that
OPG administration to OPG−/− mice reverses the bone
phenotype but can only prevent, not reverse, vascular cal-
cification [37]. In postmenopausal osteoporosis women,
and in rats, the administration of OPG reduces bone re-
sorption and therefore bone turnover [38, 39]. London et
al [40] recently demonstrated in CKD-5 patients that low
bone turnover by biopsy was associated with increased
vascular calcification and in a study of CKD-5 patients by
Coen et al [41], elevations in serum OPG were associated
with low turnover bone disease. Thus, the patients with
the higher OPG levels may have had lower bone turnover,
which does not allow bone to take up a mineral load [42],
thereby leading to extraskeletal calcification. However,
others have found that elevated OPG in CKD-5 patients
was associated with high turnover bone disease [43]. This
conflicting data are likely due to the complex interaction
of PTH and OPG, and more research is required to fully
understand the physiologic function of OPG in vascular
calcification.
In contrast to fetuin-A and OPG, MGP expression ap-
pears to be predominantly a local regulator of vascular
calcification. MGP knockout mice have excessive carti-
lage and growth plate mineralization and excessive ar-
terial medial calcification [14]. In patients undergoing
cardiac valve replacement warfarin is associated with in-
creased valve calcification [44], and in dialysis patients,
warfarin is associated with calcific uremic arteriolopathy
[45]. The mechanism by which MGP inhibits extraskele-
tal calcification appears to be via modulation of bone
morphogenic protein-2 (BMP-2) activity, and BMP-2 is
known to induce vascular calcification [22, 46]. In the
present study we demonstrated expression of MGP in the
inferior epigastric artery, with increased expression asso-
ciated with increased calcification. The antibody used in
the present study was against total MGP, and thus we can-
not confirm whether the MGP was active or not. Nonethe-
less, these results confirm that MGP is up-regulated in the
presence of arterial calcification in humans as has been
previously demonstrated in arteries from non-CKD pa-
tients [47, 48]. In addition, we demonstrated that MGP
expression was minimal in BVSMCs that were not min-
eralizing, similar to recent data by Zebboudj, Shin, and
Bostrom [49]. However, it increased with progressive
mineralization in BVSMCs and further increased in the
presence of uremic serum compared to normal serum,
even when normalized for the increased calcification in
the presence of uremic serum. This data confirms that
MGP is increased in vitro in response to mineralization
as has been previously shown [49, 50]. The data also im-
ply that MGP is not defective in the presence of pooled
uremic serum. In addition, we measured serum levels of
MGP, but found no association with the presence of arte-
rial calcification in the CKD patients. This is in contrast to
the study by Jono et al [51], demonstrating an association
of low MGP levels in non-CKD patients with coronary
artery calcification. These differences may be due to a
small sample size in our study, or different assays. Alter-
natively, circulating MGP levels in CKD-5 patients may
not reflect the increased local activity. Thus, at the present
time, there is no data supporting abnormal function of
MGP in uremia to account for the increased vascular cal-
cification in CKD patients, although additional studies
are required.
CONCLUSION
We have presented in vivo, ex vivo, and in vitro stud-
ies supporting that naturally occurring calcification in-
hibitors are important in the excess vascular calcification
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observed in CKD-5. Although more work is required to
fully elucidate the precise role of these inhibitors, we can
hypothesize the following. Fetuin-A appears to function
as a circulating inhibitor, as a decrease in the serum level
in CKD is associated with increased calcification. This is
likely due to a deficiency of this important naturally occur-
ring inhibitor that binds calcium phosphate as a soluble
complex for efficient clearance, and/or that the available
fetuin-A is depleted in dealing with the elevated serum
calcium phosphate product so commonly found in CKD.
What remains unclear is the process by which fetuin-A
is deposited into the arterial wall, and the fate of these
deposits. We believe that the predominant reason that
elevated serum levels of OPG in CKD patients and the
general population are associated with increased vascu-
lar calcification, is due to a primary effect of OPG on
bone turnover, the natural reservoir for mineral. Thus,
when OPG is elevated, there is less bone turnover, im-
pairing the ability of bone to take up a calcium load.
In contrast, MGP functions locally and our data suggest
that this inhibitor is appropriately functional in CKD. It
should be emphasized that our in vivo and ex vivo data are
associations, and not direct cause-effect because of the
cross-sectional nature of the studies, and that further
work using in vitro models and animal models is nec-
essary. Despite this limitation, the data are intriguing
and suggest that not only is calcification an active cell-
mediated process, but that there are natural defenses to
calcification. This implies that augmenting these defenses
may have an important therapeutic potential in prevent-
ing the devastating effects of vascular calcification ob-
served in CKD patients.
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